Oncopharmpod
Ruby Trial & Quizartinib Toxicity
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:14:29
- More information
Informações:
Synopsis
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
USA
